Single-cell analysis reveals distinct immune characteristics of hepatocellular carcinoma in HBV-positive versus HBV-negative cases DOI Open Access
K. Liu, Erbao Chen, Jiaming Liang

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Дек. 30, 2024

Abstract Infection with the Hepatitis B virus (HBV) is a key risk factor for Hepatocellular carcinoma (HCC) development and progression. It widely recognized that immunopathological mechanisms are pivotal in developing HBV-related HCC. Nevertheless, specific by which HBV-induced modifications within tumor microenvironment (TME) contribute to HCC pathogenesis still not well understood. Here, we utilized single-cell RNA sequencing analyze compare immune landscapes between HBV-positive HBV-negative We discovered HBV infection significantly modifies cell makeup state, leads suppression exhaustion of T cells TME. Specifically, an increase SLC4A10+ CD8+ IFITM3+ macrophages was observed, along upregulation gene SLC35F1 various subtypes. These findings offer valuable insights into alteration immunological associated infection, suggesting possible targets immunotherapeutic intervention.

Язык: Английский

Preclinical insights into the potential of itaconate and its derivatives for liver disease therapy DOI
Xiaodong Wu, Yanhong Song, Zhengwei Yuan

и другие.

Metabolism, Год журнала: 2025, Номер unknown, С. 156152 - 156152

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Sorafenib and Treg Differentiation: A Paradigm Shift in Hepatocellular Carcinoma Management DOI Creative Commons
Hanyang Liu

Cellular and Molecular Gastroenterology and Hepatology, Год журнала: 2025, Номер unknown, С. 101478 - 101478

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand? DOI Open Access
Hirak Pahari,

Javid Ahmad Peer,

Shikhar Tripathi

и другие.

World Journal of Gastrointestinal Pharmacology and Therapeutics, Год журнала: 2024, Номер 15(5)

Опубликована: Сен. 3, 2024

Liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) and chronic liver disease (CLD) is limited by factors such as tumor size, number, portal venous or hepatic invasion extrahepatic disease. Although previously established criteria, Milan UCSF, have been relaxed globally to accommodate more potential recipients comparable 5-year outcomes, there still a subset of the population that has advanced HCC without vein thrombosis detectable spread who do not qualify are unable be downstaged conventional methods for transplantation. Immune checkpoint inhibitors (ICI) atezolizumab, pembrolizumab, nivolumab given hope this group patients. We completed comprehensive literature review using PubMed, Google Scholar, reference citation analysis, CrossRef. The search utilized keywords 'liver transplant', 'HCC', 'hepatocellular carcinoma', 'immune inhibitors', 'ICI', 'atezolizumab', 'nivolumab'. Several case reports documented successful downstaging atezolizumab/bevacizumab combination prior LT, acceptable early outcomes other criteria. Adverse effects ICI also reported during perioperative period. In cases, 1.5-month interval between therapy LT suggested. Overall, results immunotherapy were encouraging promising. Early suggested ray CLD HCC, especially those multifocal branch thrombosis. However, prospective studies further experience will reveal optimal dosage, duration, timing evaluate both short- long-term terms rejection, infection, recurrence rates, survival.

Язык: Английский

Процитировано

1
Activatable fluorescent probes for imaging and diagnosis of hepatocellular carcinoma DOI Creative Commons

Xiaoxiao Men,

Fanghong Liu, Maolian Gong

и другие.

Journal of Innovative Optical Health Sciences, Год журнала: 2024, Номер unknown

Опубликована: Дек. 20, 2024

Liver cancer, specifically hepatocellular carcinoma (HCC), is a malignant neoplasm of the digestive system, characterized by exceptionally high morbidity and mortality rates on global scale. Early detection diagnosis are critical measures for enhancing prognosis patients diagnosed with HCC. An improved significantly reliant timely disease effective therapeutic monitoring. Activatable fluorescent probes essential detecting imaging biomarkers related to in vivo imaging. This paper reviews developed over past five years noninvasive optical modality demonstrates significant promise targeting pathological sites anticipated facilitate potential clinical translation.

Язык: Английский

Процитировано

1
Single-cell analysis reveals distinct immune characteristics of hepatocellular carcinoma in HBV-positive versus HBV-negative cases DOI Open Access
K. Liu, Erbao Chen, Jiaming Liang

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Дек. 30, 2024

Abstract Infection with the Hepatitis B virus (HBV) is a key risk factor for Hepatocellular carcinoma (HCC) development and progression. It widely recognized that immunopathological mechanisms are pivotal in developing HBV-related HCC. Nevertheless, specific by which HBV-induced modifications within tumor microenvironment (TME) contribute to HCC pathogenesis still not well understood. Here, we utilized single-cell RNA sequencing analyze compare immune landscapes between HBV-positive HBV-negative We discovered HBV infection significantly modifies cell makeup state, leads suppression exhaustion of T cells TME. Specifically, an increase SLC4A10+ CD8+ IFITM3+ macrophages was observed, along upregulation gene SLC35F1 various subtypes. These findings offer valuable insights into alteration immunological associated infection, suggesting possible targets immunotherapeutic intervention.

Язык: Английский

Процитировано

0